This week, Israel-based Protalix BioTherapeutics, Inc, announced positive results from a phase 2 clinical trial for its orally administered anti–tumor necrosis factor (anti-TNF) drug, OPRX-106, a plant cell–expressed recombinant human TNF receptor II fused to an IgG1 Fc domain.
This week, Israel-based Protalix BioTherapeutics, Inc, announced positive results from a phase 2 clinical trial for its orally administered anti—tumor necrosis factor (anti-TNF) drug, OPRX-106, a plant cell–expressed recombinant human TNF receptor II fused to an IgG1 Fc domain.
Protalix says that OPRX-106 met its key efficacy endpoints in the open-label, 2-arm study of OPRX-106 in 24 patients with mild to moderate ulcerative colitis (UC). Among the patients, who were randomized to receive oral administration of either 2 mg or 8 mg of the study drug once daily for 8 weeks, 67% experienced a clinical response and 28% achieved clinical remission.
Other key efficacy endpoints were also met, with 72% of patients showing improvement in rectal bleeding scores, 72% of patients demonstrating an improvement in fecal calprotectin, and 61% of patients showing an improved Gebos score (a histopathological scoring for the assessment of disease activity in UC).
At week 8, improved Mayo scores were observed in 89% of patients, with an average decrease in Mayo score of 45%—or 3 points—from baseline. No anti-drug antibodies were detected, and Protalix says that only mild to moderate adverse events were reported, with headaches being the most common.
“We are very excited by these results,” said Moshe Manor, president and CEO of Protalix. “They demonstrate efficacy and a lack of immunogenicity together with a favorable safety profile, which could potentially overcome one of the most challenging drawbacks of current ulcerative colitis therapies administered via injection and infusion.”
In January 2018, the company reported positive interim data from the first 14 patients to complete 8 weeks of treatment. The interim data demonstrated that 57% of patients achieved clinical response at week 8 and 36% achieved clinical remission.
Protalix is not the first to attempt to deliver anti-TNF therapy in an oral administration; in 2016, Avaxia Biologics reported positive results of a first-in-human trial of its AVX-470, a polyclonal bovine-derived anti-TNF drug, in patients with UC, saying that the agent was safe and well tolerated in the trial. However, Circle33 LLC, which later acquired Avaxia’s patents for the drug, has not reported any further developments.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.